# SG301-SC Injection Safety Study in Subjects With Primary ITP Patients

> **NCT07710248** · PHASE2 · RECRUITING · sponsor: **Hangzhou Sumgen Biotech Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **DRUG:** low dose group
- **DRUG:** high dose group
- **DRUG:** Placebo group

## Key facts

- **NCT ID:** NCT07710248
- **Lead sponsor:** Hangzhou Sumgen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-11
- **Primary completion:** 2027-05-17
- **Final completion:** 2027-05-17
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07710248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07710248, "SG301-SC Injection Safety Study in Subjects With Primary ITP Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07710248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*